The Efficacy and Safety of Insulin Degludec/Liraglutide Combination (IDegLira) in Patients With Type 2 Diabetes

NCT06408532 · Not yet recruiting

Last updated 2026-05-28

This clinical trial tested the combination of insulin degludec and liraglutide (IDegLira) in adults with type 2 diabetes to evaluate its effects on blood sugar control.

Status Not yet recruiting Approved but enrollment has not started.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, single-blind treatment study

Participants 256 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2024-04 · est. completion 2025-02

What this study is testing ClinicalTrials.gov NCT06408532 ↗

Description as written by the study sponsor.

The study aims to evaluate the efficacy and safety of IDegLira in type 2 diabetes who have failed premixed insulin therapy. The study plans to enroll 256 participants with inadequate glycemic control despite twice-daily subcutaneous injections of premixed insulin and metformin. Participants will be randomly assigned to either the premixed insulin dose optimization group (control group) or IDegLira once daily group, and the difference in change in glycated hemoglobin levels from baseline to 16 weeks of treatment will be assessed between the two groups.

Treatments tested

IDegLira Drug

The participants in this group will be switched to IDegLira once daily injection therapy.
Premixed insulin Drug

The participants in this group will be have optimized premixed insulin regimen.

Main thing measured	Hemoglobin A1c (HbA1c)
Sponsor	Peking University People's Hospital
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06408532 ↗